<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37056777</PMID><DateCompleted><Year>2023</Year><Month>04</Month><Day>17</Day></DateCompleted><DateRevised><Year>2023</Year><Month>04</Month><Day>24</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1664-3224</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><PubDate><Year>2023</Year></PubDate></JournalIssue><Title>Frontiers in immunology</Title><ISOAbbreviation>Front Immunol</ISOAbbreviation></Journal><ArticleTitle>Editorial: Immune determinants of COVID-19 protection and disease: A focus on asymptomatic COVID and long COVID.</ArticleTitle><Pagination><StartPage>1185693</StartPage><MedlinePgn>1185693</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1185693</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fimmu.2023.1185693</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Polyak</LastName><ForeName>Maria J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Department of Microbiology, Immunology, and Infectious Diseases, Cumming School of Medicine, Calgary, AB, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abrahamyan</LastName><ForeName>Levon</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Faculty of Veterinary Medicine, University of Montreal, Saint-Hyacinthe, QC, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bego</LastName><ForeName>Mariana G</ForeName><Initials>MG</Initials><AffiliationInfo><Affiliation>BioMedicine Design, Pfizer (United States), New York, NY, United States.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>10029030</GrantID><Agency>CIHR</Agency><Country>Canada</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016421">Editorial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>03</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Immunol</MedlineTA><NlmUniqueID>101560960</NlmUniqueID><ISSNLinking>1664-3224</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentOn"><RefSource>Editorial on the Research Topic Immune determinants of COVID-19 protection and disease: A focus on asymptomatic COVID and long COVID</RefSource></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086742" MajorTopicYN="N">COVID-19 Testing</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID - 19</Keyword><Keyword MajorTopicYN="N">SARS &#x2013; CoV &#x2013; 2</Keyword><Keyword MajorTopicYN="N">asymptomatic</Keyword><Keyword MajorTopicYN="N">immune activation</Keyword><Keyword MajorTopicYN="N">long Covid</Keyword></KeywordList><CoiStatement>Author MB is employed at Pfizer Inc. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>3</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>3</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>4</Month><Day>17</Day><Hour>6</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>4</Month><Day>14</Day><Hour>2</Hour><Minute>33</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>4</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>3</Month><Day>28</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37056777</ArticleId><ArticleId IdType="pmc">PMC10086613</ArticleId><ArticleId IdType="doi">10.3389/fimmu.2023.1185693</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC. Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): A review. JAMA (2020) 324(8):782&#x2013;93. doi:&#xa0;10.1001/jama.2020.12839</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.12839</ArticleId><ArticleId IdType="pubmed">32648899</ArticleId></ArticleIdList></Reference><Reference><Citation>Oran DP, . Topol EJ. Prevalence of asymptomatic SARS-CoV-2 infection: A narrative review. Ann Intern Med (2020) 173:362&#x2013;7. doi:&#xa0;10.7326/M20-3012</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/M20-3012</ArticleId><ArticleId IdType="pmc">PMC7281624</ArticleId><ArticleId IdType="pubmed">32491919</ArticleId></ArticleIdList></Reference><Reference><Citation>Pijls BG, Jolani S, Atherley A, Derckx RT, Dijkstra JIR, Franssen GHL, et al. . Demographic risk factors for COVID-19 infection, severity, ICU admission and death: A meta-analysis of 59 studies. BMJ Open (2021) 11(1):e044640. doi:&#xa0;10.1136/bmjopen-2020-044640</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2020-044640</ArticleId><ArticleId IdType="pmc">PMC7802392</ArticleId><ArticleId IdType="pubmed">33431495</ArticleId></ArticleIdList></Reference><Reference><Citation>Ludvigsson JF. Systematic review of COVID-19 in children shows milder cases and a better prognosis than adults. Acta Paediatr (2020) 109(6):1088&#x2013;95. doi:&#xa0;10.1111/apa.15270</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/apa.15270</ArticleId><ArticleId IdType="pmc">PMC7228328</ArticleId><ArticleId IdType="pubmed">32202343</ArticleId></ArticleIdList></Reference><Reference><Citation>Morrissey SM, Geller AE, Hu X, Tieri D, Ding C, Klaes CK, et al. . A specific low-density neutrophil population correlates with hypercoagulation and disease severity in hospitalized COVID-19 patients. JCI Insight (2021) 6(9):e148435. doi:&#xa0;10.1172/jci.insight.148435</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci.insight.148435</ArticleId><ArticleId IdType="pmc">PMC8262329</ArticleId><ArticleId IdType="pubmed">33986193</ArticleId></ArticleIdList></Reference><Reference><Citation>Markarian NM, Galli G, Patel D, Hemmings M, Nagpal P, Berghuis AM, et al. . Identifying markers of emerging SARS-CoV-2 variants in patients with secondary immunodeficiency. Front Microbiol (2022) 13:933983. doi:&#xa0;10.3389/fmicb.2022.933983</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmicb.2022.933983</ArticleId><ArticleId IdType="pmc">PMC9283111</ArticleId><ArticleId IdType="pubmed">35847101</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>